IVA - Inventiva Sa
Inventiva Sa Logo

IVA - Inventiva Sa

https://inventivapharma.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bearish
American Outdoor Brands Posts Downbeat Results, Joins Lululemon, Quanex Building And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Copart ( NASDAQ:CPRT ) , American Outdoor Brands ( NASDAQ:AOUT )
Benzinga • 1 week, 3 days ago • score: -0.54
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 100 points on Friday. Shares of American Outdoor Brands Inc AOUT fell sharply in pre-market trading after the company reported first-quarter EPS and sales below estimates.
Bullish
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
GlobeNewswire • 2 months ago • score: 0.19
Daix ( France ) , New York City ( New York, United States ) , July 9, 2025 - Inventiva ( Euronext Paris and Nasdaq: IVA ) ( "Inventiva" or the "Company" ) , a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic ...
Bullish
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance - Inventiva ( OTC:IVEVF ) , Inventiva ( NASDAQ:IVA )
Benzinga • 2 months ago • score: 0.17
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality Assurance
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France.

52W High
$6.50
52W Low
$1.53
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.74
Valuation
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.35
EV/Revenue (<3 favorable)
62.91
P/S (TTM) (<3 favorable)
54.96
P/B (<3 favorable)
2.10
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
5.16%
Shares Outstanding
139,060,000
Float
50,519,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-03-31 (Overview)
Revenue (TTM)
14,094,000
Gross Profit (TTM)
12,697,000
EPS (TTM)
-3.59
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-3.84%
ROE (TTM) (>15% strong)
-16.43%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.30
Momentum
Bearish momentum
Value
0.5313
Previous
0.5561
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025